Spasmopharm, 500 mg+2 mg+0.02 mg/ml 2 ml 10 pcs

Savzmofarm is a combined drug with a pronounced antispasmodic and analgesic effect.

Indications

Active ingredient

Composition

How to take, the dosage

The drug is to be administered strictly intramuscularly!

The drug is intended for short-term use!

The drug must be administered under the close supervision of a physician with emergency treatment options due to the risk of anaphylactic shock in patients with hypersensitivity to sodium metamizole or pyrazolone derivatives.

Adults and children over 15 years of age (>53 kg)

In adults and children over 15 years of age the drug is administered intramuscularly in 2-5 ml. If necessary, the dose is repeated after 6-8 hours. The maximum daily dose should not exceed 6 ml of the drug (equivalent to 3 g of sodium metamizole).

The duration of treatment is 2-3 days.

After therapeutic effect is achieved, it is allowed to switch to treatment with oral analgesics and antispasmodics.

If there is no therapeutic effect, treatment is stopped.

Patients over 65 years of age

Dose reduction is usually not necessary. In patients with age-related hepatic and renal impairment the dose must be reduced because the elimination half-life of sodium metamizole metabolites may be increased (see section “Pharmacokinetics”).

Patients with impaired renal function

Sodium metamizole is excreted in the urine as metabolites. In patients with mild to moderate renal impairment, half the adult dose is recommended.

Patients with hepatic impairment

The elimination half-life of active metabolites of sodium metamizole is increased in such patients. High doses should be avoided in patients with hepatic impairment. There is no need to reduce the dose in short-term use.

There is insufficient experience with long-term use in patients with renal or hepatic impairment.

Children

The drug is contraindicated in children under the age of 15 years (see Contraindications section).

Interaction

Combination of SPASMOFARM with other medicinal products requires special caution due to the content of sodium metamizole, which is an inducer of microsomal liver enzymes.

Indirect anticoagulants

In concomitant use, sodium metamizole may decrease the activity of coumarin anticoagulants due to induction of hepatic microsomal enzymes.

Chlorpromazine and other phenothiazine derivatives

In concomitant use with sodium metamizole there is a risk of severe hypothermia.

Cyclosporine A

Sodium metamizole decreases the plasma concentration of cyclosporine A when used concomitantly.

Chloramphenicol and other myelotoxic agents

There is an increased risk of myelosuppression when used concomitantly with sodium metamizole.

Enzyme inducers

The barbiturates glutethimide phenylbutazone may weaken the effects of sodium metamizole.

CNS depressants

CNS depressants may increase the analgesic effects of sodium metamizole.

Tricyclic antidepressants (imipramine amitriptyline) oral contraceptives analgesics allopurinol

Augmented effects when used with sodium metamizole.

Simultaneous use with other analgesics and NSAIDs increases the risk of hypersensitivity and other adverse reactions.

Pyrazolone derivatives can interact with captopril lithium methotrexate and triamterene and alter the effectiveness of hypotensive drugs diuretics. The magnitude of these interactions is unknown.

Special Instructions

When treating with SPASMOFARM there is a risk of anaphylactic reactions. At the first signs of hypersensitivity the drug administration should be stopped and urgent therapeutic measures (epinephrine glucocorticosteroids antihistamines) should be taken.

The risk of anaphylactoid reactions when using sodium metamizole is significantly increased in patients with:

– Analgesic asthma syndrome or idiosyncrasy to analgesics in the form of angioedema urticaria;

– Bronchial asthma especially accompanied by rhinosinusitis and nasal mucosal polyposis;

– chronic urticaria;

– idiosyncrasy to dyes (e.g., tartrazine) and preservatives (e.g., benzoate);

– alcohol intolerance. Such patients react to the use of a minimal amount of alcoholic beverages with symptoms such as sneezing, lacrimation and severe visual impairment. Such intolerance to alcohol can be a sign of undiagnosed “aspirin” asthma syndrome.

Spasmopharm contains sodium metamizole, which has a small but life-threatening risk of shock and agranulocytosis. The development of agranulocytosis is independent of the dose and cannot be predicted. It can occur after the first dose or after multiple doses. Typical signs of agranulocytosis are fever, sore throat, painful swallowing, inflammation of the mucous membrane of the mouth, nose, pharynx, and anorectal genital area. In case of a sudden worsening of the general state and signs of agranulocytosis the drug should be discontinued immediately without waiting for laboratory confirmation.

When treating with SPASMOFARM patients with hematologic diseases or those with a history of such diseases, hematologic status should be monitored during treatment.

The drug should be used with caution in patients with obstructive diseases of the gastrointestinal tract (achalasia cardia pyloroduodenal stenosis). Repeated use of the drug SPAZMOFARM in these cases may cause delayed evacuation of gastrointestinal contents and intoxication. Administration of SPASMOFARM in patients with gastroesophageal reflux disease intestinal atony paralytic intestinal obstruction glaucoma myasthenia gravis heart disease (arrhythmias coronary heart disease chronic heart failure) requires special caution and medical supervision.

Sodium metamizole as a component of SPASMOFARM may cause hypotensive reactions (see section “Side effects”). These reactions are dose-dependent and more common with parenteral use.

The risk of these reactions is increased in the following cases:

– in patients with a history of arterial hypotension with decreased fluid volume and electrolyte content or dehydration unstable hemodynamics or circulatory insufficiency (e.g., patients with myocardial infarction or polytrauma);

– in patients with elevated body temperature.

In these patients, careful evaluation of the need for the drug and close monitoring may require therapeutic measures (e.g., circulatory stabilization) to reduce the risk of arterial hypotension. SPASMOFARM should only be used when carefully monitoring hemodynamics in patients who do not require mandatory forced lowering of blood pressure such as those with severe coronary heart disease or cerebral stenosis.

Spasmopharm should only be used after careful assessment of the benefit/risk ratio and appropriate precautions should be taken in patients with renal or hepatic impairment (see section “Dosage and administration”).

Phenpiperinia bromide has m-choline-blocking effects and may cause dizziness and impaired accommodation. Sodium metamizole may adversely affect the ability to concentrate and leads to decreased responsiveness.

Patients driving or operating machinery should be warned about possible adverse reactions to the drug. Activities requiring increased attention should be discontinued until the adverse reactions disappear.

Overdose

Pregnancy use

Pregnancy

The results of animal studies indicate that the drug has no embryotoxic and teratogenic potential. Strictly controlled studies in pregnant women have not yet been conducted.

While sodium metamizole is a weak inhibitor of prostaglandin synthesis the possibility of premature closure of the arterial (Botall’s) duct as well as perinatal complications due to decreased platelet aggregation of the fetus and mother cannot be excluded so the drug is contraindicated in pregnancy.

Breast-feeding

Because metabolites of sodium metamizole are excreted with the breast milk, breast-feeding should be stopped if the drug must be used.

Similarities